DNB Asset Management Expands Enovix Position as Execution Risks Persist

What happened

DNB Asset Management AS increased its stake in Enovix Corporation by 378.6% during the third quarter, purchasing 166,712 shares as per a recent 13F filing. This move comes amid Enovix's critical phase, where it is ramping up Fab2 manufacturing in Malaysia and seeking commercial adoption of its AI-1 silicon-anode batteries for smartphones. Despite reporting 85% year-over-year revenue growth to $7.99 million in Q3 2025, Enovix's sales are still dominated by low-margin defense contracts, with Fab2 and high-volume consumer electronics contributions remaining minimal. The company holds $648 million in cash, providing a financial runway, but its $1.6 billion equity valuation hinges on unproven execution milestones like Fab2 yield improvements and smartphone design wins. DNB's increased position reflects institutional optimism but does not address the substantial execution risks highlighted in the DeepValue report, such as manufacturing inefficiencies and delayed commercialization.

Implication

DNB's expanded investment suggests some institutions believe in Enovix's technology despite current headwinds, yet this does not change the fundamental need for Fab2 to demonstrate competitive yields and revenue contribution. Investors should recognize that Enovix's stock trajectory will depend on near-term catalysts, including Fab2 revenue attribution and confirmed AI-1 smartphone launches. The cash reserve offers a buffer, but persistent execution delays could lead to further dilution or value destruction. Moreover, the market sentiment has cooled from a growth story to an execution-focused narrative, with consensus ratings at 'Hold' despite high target prices. Therefore, while DNB's move is a positive signal, it does not warrant a shift from the cautious 'WAIT' stance advised in the DeepValue report, as core risks remain unaddressed.

Thesis delta

The DNB stake increase does not materially alter the investment thesis for Enovix, which remains centered on Fab2 achieving profitable utilization and securing high-volume smartphone design wins. This news is a minor positive signal but fails to reduce the execution risks or change the fundamental need for visible progress in manufacturing and commercialization. Consequently, the thesis retains a 'WAIT' rating until clearer evidence emerges, as the purchase does not address the underlying operational uncertainties.